A dynamic total-body PET/CT study using [68Ga]Ga-HER2 Affibody in HER2-positive breast cancer patients mapped organ biodistribution and identified the earliest feasible imaging window at 45 minutes post-injection. The work also reported an effective dose estimate and quantified tracer distribution over time. For centers considering immuno-PET workflows, the timing insight may help reduce scan burden while maintaining diagnostic usability. It also supports standardization conversations around total-body PET protocols for affibody-based HER2 targeting. The study’s operational output—dose and earliest imaging time—can directly influence scheduling, throughput, and patient experience in prospective clinical adoption.